Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Mereo BioPharma Group plcNASDAQ: MREO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $6.72M (cash outflow) fell 47.9% year over year, behind the -24.3% change in trailing-twelve-month net income. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Net income amounted to 8375.6% of revenue in FY2025.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$9.86M (-76.5%) for the fiscal year ending Dec 2026, a slowdown from the -3.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.72M-8.6% QoQ
Last fiscal yearDec 2025
-$41.88M-3.2% YoY
LTMMar 2026
-$35.71M-24.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.9%-91.2%-43.3 pp
1 year-3.2%-76.5%-73.3 pp
3-year CAGR-0.3%-36.8%-36.5 pp
5-year CAGR-40.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(41.88M) USD
Year-over-year change
+3.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -24.3% is the 9th highest of 10, against a peer median of +37.5%.
  • Net income amounts to 7142.0% of revenue for MREO, versus a peer median of 1593.3%.
MREO Competitors
Net Income for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$80.71B USD+146477.0%+53.5%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$156.4M USD+7.6%+77.4%—
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$87.5M USD-19.9%+19.0%—
ACIUAC Immune S.A.LTM Dec 2025CHF 70.34M CHF+38.1%-1.7%1968.6%
IMMPImmutep LimitedFY2025A$61.43M AUD+43.8%+24.0%1218.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$58.44M USD+17.3%+35.2%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$54.42M USD+37.5%+26.7%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
MREOMereo BioPharma Group plcLTM Mar 2026$35.71M USD-24.3%-0.3%7142.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$27.37M USD-52.6%-18.3%—
Peer median (excluding MREO) —+37.5%+22.4%1593.3%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.